Lead Sponsor

Masonic Cancer Center, University of Minnesota

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age≥ 18 years
•Cohort A: Patients undergoing intensive induction chemotherapy for acute myeloid leukemia (AML; newly diagnosed or relapsed/refractory).
•\* Any intensive regimen with planned \~4 weeks of inpatient stay
•Cohort B: Allo-HCT patients
•\* Any allogeneic transplant regimen with planned GVHD prophylaxis containing generic IV Mycophenolate Mofetil (MMF) and tacrolimus (Tac)
•Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control until at least six months post-FMT/placebo
•Voluntary written consent signed before performance of any study-related procedure not part of normal medical care

•Planned continuation of antibacterial antibiotics after the first neutrophil recovery (ANC \> 1,000)
•Patients who are currently receiving or recently received (within 28 days) other investigational agents.
•Pregnant or breast feeding. The FDA has not classified this agent into a specified pregnancy category. Females of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy